AR and renal cell carcinoma: Moreover, enzalutamide, an anti-androgen, enhances SPOP-driven degradation of AR and improves the anticancer effect of the receptor tyrosine kinase inhibitor sunitinib in AR-positive RCC (Adelaiye-Ogala et al., 2018).